Download PDFPDF
From inhibition of radiographic progression to maintaining structural integrity: a methodological framework for radiographic progression in rheumatoid arthritis and psoriatic arthritis clinical trials
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    Visualization of structural damage as a surrogate marker of radiographic progression in patients with rheumatoid arthritis
    • Alexander Pfeil
    • Other Contributors:
      • Peter Oelzner, Diane M. Renz, Gabriele Lehmann, Gunter Wolf, Joachim B?ttcher

    Dear Editor,

    The article published by Landewe et al. (1) offers novel insights to assess the benefits of new therapeutic strategies in rheumatoid arthritis (RA) which focus more on [the visualization of] structural integrity rather than the inhibition of radiographic progression (1). The authors clearly outline the three major problems of the common superiority study designs:
    I. Differences in progression are...

    Show More
    Conflict of Interest:
    None declared.